Scientists Unveil The Unexpected Playbook Behind mRNA Cancer Vaccines' Success

In 2020, mRNA vaccines emerged as dark horses that reshaped the course of the COVID-19 pandemic. Now, this Nobel Prize–winning technology is turning its sights on cancer. Around the world, mRNA vaccines targeting solid tumors such as melanoma, small-cell lung cancer, and bladder cancer have entered clinical trials. In 2023 alone, nearly 20 million new cancer cases were reported globally, with more than 90% of cancer deaths attributable to the invasion and metastasis of solid tumors. Yet the central question has remained: how exactly do mRNA vaccines “teach” the immune system to recognize and eliminate cancer cells?

According to conventional wisdom, a type of immune cell known as type 1 classical dendritic cells (cDC1) is the “gold-standard instructor” for activating CD8+ T cells. Whether in viral infections, tumor development, or conventional protein and DNA vaccines, cDC1 cells—thanks to their high-efficiency cross-presentation—are thought to shoulder most of the burden of activating CD8+ T cells with exogenous antigens. Do lipid nanoparticle (LNP)–encapsulated mRNA vaccines follow the same rule?

A recent study published in Nature, titled “mRNA vaccines engage unconventional pathways in CD8+ T cell priming,” by scientists from Washington University School of Medicine and other institutions, provides a surprising answer: mRNA-LNP vaccines do not need to rely on the cDC1 “main highway” at all. Instead, they engage two redundant routes that involve both cDC1 and their “cousins,” cDC2.

In mouse studies, the researchers found that even in the absence of cDC1 cells, mRNA cancer vaccines could still elicit robust anti-tumor T cell responses and successfully clear sarcomas—malignant tumors arising in connective tissues such as fat and muscle. This finding overturns textbook immunology, because cDC2 cells have traditionally been considered nonparticipants in CD8+ T cell responses induced by conventional vaccines. It also helps explain the exceptional potency of mRNA vaccines and points to clear targets for optimizing future cancer vaccine design.

Using gene knockout mouse models, the team dissected the roles of different dendritic cell subsets and showed that mRNA-LNP vaccines recruit cDC1 and cDC2 in a redundant fashion. Even more intriguingly, although the T cells activated by each subset bear slightly different molecular “fingerprints,” both populations can drive effective anti-tumor responses and form immune memory. In other words, the immune system provides mRNA vaccines with a built-in “double insurance” mechanism—if one road is blocked, the other still works.

Figure 1. CD8+ T cells activated by cDC2 cells are capable of exerting anti-tumor effects. (JO, Suin, et al., 2026)

The researchers also uncovered a distinctive way that cDC2 cells activate T cells: cross-dressing. In simple terms, certain non-hematopoietic cells (such as tumor or stromal cells) first produce antigen proteins according to the mRNA instructions, process them into peptides, and display them on their own MHC-I molecules. These cells then transfer the peptide–MHC–bearing membrane complexes wholesale to cDC2 cells, which use this “ready-made evidence” to activate T cells. This process depends on type I interferon signaling and completely bypasses the WDFY4-dependent cross-presentation pathway typically used by cDC1. In other words, mRNA vaccines enable cDC2 to activate T cells using antigens “borrowed” from other cells.

The implications go well beyond basic immunology. In the clinic, cancer patients’ responses to mRNA vaccines can vary substantially, potentially reflecting differences in the relative abundance or functional state of cDC1 and cDC2 within individuals. Since both routes can be effective, future vaccine designs need not “bet everything” on cDC1 alone; they can aim to co-activate both subsets and even harness cross-dressing to boost cDC2 presentation efficiency. As the researchers quipped, cDC1 are like full-time professors, while cDC2 are largely self-taught but capable teaching assistants—usually quiet, yet perfectly able to carry the day when it counts.

This study was conducted in mouse models, and the human immune system is more complex. Even so, it opens a new window: the striking potential of mRNA vaccines in cancer therapy may stem from their willingness to “take the road less traveled,” mobilizing long-overlooked “bench players” in the immune system. For patients awaiting more effective treatments, this is an encouraging sign.